An epidemiological study to assess Plasmodium falciparum parasite prevalence and malaria control measures in Burkina Faso and Senegal

Aldiouma Diallo, Ali Sié, Sodiomon Sirima, Khadime Sylla, Mahmadou Ndiaye, Mamadou Bountogo, Espérance Ouedraogo, Roger Tine, Assane Ndiaye, Boubacar Coulibaly, Alphonse Ouedraogo, Babacar Faye, El Hadji Ba, Guillaume Compaore, Alfred Tiono, Cheikh Sokhna, Maurice Yé, Amidou Diarra, Edith Roset Bahmanyar, Melanie De Boer, Jean-Yves Pirçon, Effua Abigail Usuf, Aldiouma Diallo, Ali Sié, Sodiomon Sirima, Khadime Sylla, Mahmadou Ndiaye, Mamadou Bountogo, Espérance Ouedraogo, Roger Tine, Assane Ndiaye, Boubacar Coulibaly, Alphonse Ouedraogo, Babacar Faye, El Hadji Ba, Guillaume Compaore, Alfred Tiono, Cheikh Sokhna, Maurice Yé, Amidou Diarra, Edith Roset Bahmanyar, Melanie De Boer, Jean-Yves Pirçon, Effua Abigail Usuf

Abstract

Background: Malariometric information is needed to decide how to introduce malaria vaccines and evaluate their impact in sub-Saharan African countries.

Methods: This cross-sectional study (NCT01954264) was conducted between October and November, 2013, corresponding to the high malaria transmission season, in four sites with Health and Demographic Surveillance Systems (DSS) [two sites with moderate-to-high malaria endemicity in Burkina Faso (Nouna and Saponé) and two sites with low malaria endemicity in Senegal (Keur Socé and Niakhar)]. Children (N = 2421) were randomly selected from the DSS lists of the study sites and were stratified into two age groups (6 months-4 years and 5-9 years). A blood sample was collected from each child to evaluate parasite prevalence of Plasmodium falciparum and other Plasmodium species and gametocyte density by microscopy, and rapid diagnosis test in the event of fever within 24 h. Case report forms were used to evaluate malaria control measures and other factors.

Results: Plasmodium falciparum was identified in 707 (29.2%) children, with a higher prevalence in Burkina Faso than Senegal (57.5 vs 0.9% of children). In Burkina Faso, prevalence was 57.7% in Nouna and 41.9% in Saponé in the 6 months-4 years age group, and 75.4% in Nouna and 70.1% in Saponé in the 5-9 years age group. Infections with other Plasmodium species were rare and only detected in Burkina Faso. While mosquito nets were used by 88.6-97.0 and 64.7-80.2% of children in Burkina Faso and Senegal, other malaria control measures evaluated at individual level were uncommon. In Burkina Faso, exploratory analyses suggested that use of malaria treatment or any other medication within 14 days, and use of insecticide spray within 7 days decreased the prevalence of malaria infection; older age, rural residence, natural floor, grass/palm roof, and unavailability of electricity in the house were factors associated with increased malaria occurrence.

Conclusions: Plasmodium falciparum infection prevalence in children younger than 10 years was 57.5% in Burkina Faso and 0.9% in Senegal, and variability was observed, among others, by age, study site and malaria control measures.

Keywords: Burkina Faso; Epidemiological study; Malaria; Parasite prevalence; Preventive interventions; Risk factors; Senegal.

Figures

Fig. 1
Fig. 1
Plasmodium falciparum parasite prevalence, annual rainfall and enrolment period for the study center of a Nouna (Burkina Faso), b Saponé (Burkina Faso), c Niakhar (Senegal), and d Keur Socé (Senegal). PP parasite prevalence, M months, Y years
Fig. 2
Fig. 2
Plasmodium falciparum parasite prevalence by site according to age. 95% CI 95% confidence interval

References

    1. WHO Malaria vaccine: WHO position paper. Wkly Epidemiol Rec. 2016;91:33–51.
    1. WHO. World malaria report. Geneva: World Health Organization; 2014. . Accessed 23 May 2016.
    1. Meeting of the Strategic Advisory Group of Experts on Immunization Conclusions and recommendations. Wkly Epidemiol Rec. 2015;2015(90):681–699.
    1. The RTS,S Clinical Trials Partnership Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685. doi: 10.1371/journal.pmed.1001685.
    1. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–467. doi: 10.1056/NEJMoa0808859.
    1. Noor AM, Kinyoki DK, Mundia CW, Kabaria CW, Mutua JW, Alegana VA, et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000–10: a spatial and temporal analysis of transmission intensity. Lancet. 2014;383:1739–1747. doi: 10.1016/S0140-6736(13)62566-0.
    1. Protopopoff N, Matowo J, Malima R, Kavishe R, Kaaya R, Wright A, et al. High level of resistance in the mosquito Anopheles gambiae to pyrethroid insecticides and reduced susceptibility to bendiocarb in north-western Tanzania. Malar J. 2013;12:149. doi: 10.1186/1475-2875-12-149.
    1. Breman JG. Eradicating malaria. Sci Prog. 2009;92(Pt 1):1–38. doi: 10.3184/003685009X440290.
    1. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest. 2008;118:1266–1276. doi: 10.1172/JCI33996.
    1. The RTS,S Clinical Trials Partnership First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863–1875. doi: 10.1056/NEJMoa1102287.
    1. The RTS,S Clinical Trials Partnership A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284–2295. doi: 10.1056/NEJMoa1208394.
    1. The RTS,S Clinical Trials Partnership Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45. doi: 10.1016/S0140-6736(15)60721-8.
    1. European Medicines Agency (EMA). First malaria vaccine receives positive scientific opinion from EMA. EMA/CHMP/488348/2015. . Accessed 29 Feb 2016, 2015.
    1. Diboulo E, Sie A, Diadier DA, Voules DA, Ye Y, Vounatsou P. Bayesian variable selection in modelling geographical heterogeneity in malaria transmission from sparse data: an application to Nouna Health and Demographic Surveillance System (HDSS) data, Burkina Faso. Parasit Vectors. 2015;8:118. doi: 10.1186/s13071-015-0679-7.
    1. Geiger C, Agustar HK, Compaore G, Coulibaly B, Sie A, Becher H, et al. Declining malaria parasite prevalence and trends of asymptomatic parasitaemia in a seasonal transmission setting in North-Western Burkina Faso between 2000 and 2009–2012. Malar J. 2013;12:27. doi: 10.1186/1475-2875-12-27.
    1. Ilboudo-Sanogo E, Tiono BA, Sagnon N, Cuzin Ouattara N, Nebie I, Sirima SB. Temporal dynamics of malaria transmission in two rural areas of Burkina Faso with two ecological differences. J Med Entomol. 2010;47:618–624. doi: 10.1093/jmedent/47.4.618.
    1. Ndiath M, Faye B, Cisse B, Ndiaye JL, Gomis JF, Dia AT, et al. Identifying malaria hotspots in Keur Soce health and demographic surveillance site in context of low transmission. Malar J. 2014;13:453. doi: 10.1186/1475-2875-13-453.
    1. Sylla K, Tine RC, Ndiaye M, Sow D, Sarr A, Mbuyi ML, et al. Sero-epidemiological evaluation of Plasmodium falciparum malaria in Senegal. Malar J. 2015;14:275. doi: 10.1186/s12936-015-0789-x.
    1. Vafa M, Troye-Blomberg M, Anchang J, Garcia A, Migot-Nabias F. Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants. Malar J. 2008;7:17. doi: 10.1186/1475-2875-7-17.
    1. Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, Fulford AJ, et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet. 2008;372:1545–1554. doi: 10.1016/S0140-6736(08)61654-2.
    1. Ouedraogo AL, Bousema T, Schneider P, de Vlas SJ, Ilboudo-Sanogo E, Cuzin-Ouattara N, et al. Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS ONE. 2009;4:e8410. doi: 10.1371/journal.pone.0008410.
    1. Tine RCK, Faye B, Ndour CT, Sylla K, Sow D, Ndiaye M, et al. Parasitic infections among children under 5 years in Senegal: prevalence and effect on anaemia and nutritional status. ISRN Parasitol. 2013;2013:272701. doi: 10.5402/2013/272701.
    1. Ouedraogo A, Tiono AB, Diarra A, Sanon S, Yaro JB, Ouedraogo E, et al. Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso. PLoS ONE. 2013;8:e50036. doi: 10.1371/journal.pone.0050036.
    1. Lindsay S, Ansell J, Selman C, Cox V, Hamilton K, Walraven G. Effect of pregnancy on exposure to malaria mosquitoes. Lancet. 2000;355:1972. doi: 10.1016/S0140-6736(00)02334-5.
    1. Verhulst NO, Qiu YT, Beijleveld H, Maliepaard C, Knights D, Schulz S, et al. Composition of human skin microbiota affects attractiveness to malaria mosquitoes. PLoS ONE. 2011;6:e28991. doi: 10.1371/journal.pone.0028991.
    1. Gnémé A, Guelbéogo WM, Riehle MM, Tiono AB, Diarra A, Kabré GB, et al. Plasmodium species occurrence, temporal distribution and interaction in a child-aged population in rural Burkina Faso. Malar J. 2013;12:67. doi: 10.1186/1475-2875-12-67.
    1. Tiono AB, Kangoye DT, Rehman AM, Kargougou DG, Kabore Y, Diarra A, et al. Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods. PLoS ONE. 2014;9:e86936. doi: 10.1371/journal.pone.0086936.
    1. Louis VR, Schoeps A, Tiendrebeogo J, Beiersmann C, Ye M, Damiba MR, et al. An insecticide-treated bed-net campaign and childhood malaria in Burkina Faso. Bull World Health Organ. 2015;93:750–758. doi: 10.2471/BLT.14.147702.
    1. Ntonifor NN, Ngufor CA, Kimbi HK, Oben BO. Traditional use of indigenous mosquito-repellents to protect humans against mosquitoes and other insect bites in a rural community of Cameroon. East African Med J. 2006;83:553–558.
    1. Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun. 2012;3:1237. doi: 10.1038/ncomms2241.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe